Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inhibikase Therapeutics (IKT) Shares Outstanding (Weighted Average) (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Shares Outstanding (Weighted Average) for 6 consecutive years, with $90.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 913.79% to $90.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $90.1 million, a 913.79% increase, with the full-year FY2024 number at $23.7 million, up 293.35% from a year prior.
  • Shares Outstanding (Weighted Average) was $90.1 million for Q3 2025 at Inhibikase Therapeutics, roughly flat from $89.8 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $90.1 million in Q3 2025 to a low of $4.2 million in Q3 2022.
  • A 5-year average of $22.7 million and a median of $8.9 million in 2024 define the central range for Shares Outstanding (Weighted Average).
  • Peak YoY movement for Shares Outstanding (Weighted Average): crashed 77.85% in 2023, then soared 1312.1% in 2025.
  • Inhibikase Therapeutics' Shares Outstanding (Weighted Average) stood at $18.2 million in 2021, then plummeted by 76.81% to $4.2 million in 2022, then surged by 42.74% to $6.0 million in 2023, then soared by 293.35% to $23.7 million in 2024, then skyrocketed by 279.77% to $90.1 million in 2025.
  • Per Business Quant, the three most recent readings for IKT's Shares Outstanding (Weighted Average) are $90.1 million (Q3 2025), $89.8 million (Q2 2025), and $89.5 million (Q1 2025).